Bridging therapy for ischaemic stroke: tenecteplase and alteplase compared

A cheap thrombolytic appears to double the chances of reperfusion in patients with ischaemic stroke prior to thrombectomy compared with the standard drug, Australian research shows.

The double-blinded, randomised controlled phase 2 trial of 200 patients showed tenecteplase was non-inferior to alteplase and patients had better functional outcomes after its use.

Reperfusion of more than 50% of the ischaemic area or dissolution of the clot occurred in 22% of patients treated with tenecteplase compared with 10% of